Respiratory Handbook
For UK audiences

The professional's guide to product selection

Products

Mometasone furoate - Alliance Healthcare (Distribution) Ltd
Alliance Healthcare

Mometasone furoate - Alliance Healthcare (Distribution) Ltd

Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.

Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.

Mometasone furoate - Almus Pharmaceuticals Ltd
Almus

Mometasone furoate - Almus Pharmaceuticals Ltd

Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.

Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.

Mometasone furoate - DE Pharmaceuticals
DE Pharmaceuticals

Mometasone furoate - DE Pharmaceuticals

Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.

Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.

Mometasone furoate - Medihealth (Northern) Ltd
Medihealth (Northern) Ltd

Mometasone furoate - Medihealth (Northern) Ltd

Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.

Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.

Mometasone furoate - NorthStar Healthcare Unlimited Company
NorthStar

Mometasone furoate - NorthStar Healthcare Unlimited Company

For prophylaxis of asthma by inhalation of powder
• Child 12–17 years: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained.
• Adult: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained.

For prophylaxis of severe asthma by inhalation of powder
• Child 12–17 years: Increased if necessary up to 400 micrograms twice daily.
• Adult: Increased if necessary up to 400 micrograms twice daily.

Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.

Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.

Mometasone furoate - Organon Pharma (UK) Ltd
Organon Pharma

Mometasone furoate - Organon Pharma (UK) Ltd

For prophylaxis of asthma by inhalation of powder
• Child 12–17 years: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained.
• Adult: Initially 400 micrograms daily in 1–2 divided doses, single dose to be inhaled in the evening, reduced to 200 micrograms once daily, if control maintained.

For prophylaxis of severe asthma by inhalation of powder
• Child 12–17 years: Increased if necessary up to 400 micrograms twice daily.
• Adult: Increased if necessary up to 400 micrograms twice daily.

Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.

Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.

Mometasone furoate - Sandoz Ltd
Sandoz

Mometasone furoate - Sandoz Ltd

Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.

Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.

Mometasone furoate - Sigma Pharmaceuticals Plc
SIGMA Pharmaceuticals

Mometasone furoate - Sigma Pharmaceuticals Plc

Prophylaxis and treatment of allergic rhinitis by intranasal administration
• Child 3–11 years: 50 mcg daily, dose into each nostril.
• Over 12 years: 100 mcg daily, increased if necessary up to 200 mcg daily, dose into each nostril. Reduce to 50 mcg daily when controlled.

Management of nasal polyps by intranasal administration
• Adult: initially 100 mcg daily for five to six weeks, dose into each nostril, then increased if necessary to 100 mcg twice daily. Consider alternative if no improvement after five to six weeks. Reduce when controlled.

Mometasone furoate with glycopyrronium bromide and Indacaterol - Sandoz Ltd
Sandoz

Mometasone furoate with glycopyrronium bromide and Indacaterol - Sandoz Ltd

Long-acting selective beta2 agonist, long-acting muscarinic antagonist with corticosteroid.

Adult: one inhalation once daily.

Montelukast - AAH Pharmaceuticals
AAH Pharmaceuticals

Montelukast - AAH Pharmaceuticals

A leukotriene receptor antagonist that inhibits bronchoconstriction by blocking the inflammatory response in the airways.

Prophylaxis of asthma
• Child 6 months–5 years: 4 mg once daily in the evening.
• 6–14 years: 5 mg once daily in the evening
• Adult and child over 15 years: 10 mg once daily in the evening

Seasonal allergic rhinitis in patients with asthma
• Adult and child over 15 years: 10 mg once daily in the evening